ELLIE KOBASHIGAWA: Open Payments
NPI 1710670294 · LEAVENWORTH, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$929 in 44 payments from 10 companies in 2025. Trend: 2023 $394 · 2024 $907 · 2025 $929
Food & beverage: $849Education: $80
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 9 | $272 |
| Otsuka America Pharmaceutical, Inc. | 9 | $147 |
| Vanda Pharmaceuticals Inc. | 6 | $142 |
| Teva Pharmaceuticals USA, Inc. | 6 | $137 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $93 |
| Alkermes, Inc. | 3 | $64 |
| Axsome Therapeutics, Inc. | 2 | $32 |
| Tris Pharma Inc | 1 | $15 |
| Neurocrine BioSciences, Inc. | 1 | $14 |
| ABBVIE INC. | 1 | $14 |
Products named: COBENFY, ABILIFY ASIMTUFII, CAPLYTA, HETLIOZ, AUSTEDO XR, FANAPT, ARISTADA, ABILIFY MAINTENA.
Industry payments across KS — which companies pay providers there.
